PARP Inhibitors- Competitive Landscape, Market and Pipeline Analysis, 2018

PARP Inhibitors- Competitive Landscape, Market and Pipeline Analysis, 2018

  • Pages: 159
  • Geography: Global
  • Delivery Timeline: 48 Hours
  • Publication: Dec, 2017
  • SKU: DISR0017
  • Single User License
    (20% Off)
    $2,700.00
  • Site License
    (30% Off)
    $5,500.00
  • Global License
    (40% Off)
    $8,250.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

"PARP Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018", report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 15+ products along with 12+ companies involved.  AbbVie and Pfizer are among the developers of most promising pipeline products.
Products covered by Phase

• Marketed Products 

• Phase III, Phase II and Phase I 

• IND and Pre-clinical 
Overview of pipeline development activities for PARP Inhibitors
Pipeline analysis of 15+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for PARP Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy. 
Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. 
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases. 
Scope 

• The report provides competitive pipeline landscape of PARP Inhibitors

• The report provides the marketed drugs information including its sales, development activities and details of patent expiry

• The report provides the insight of current and future market for PARP Inhibitors 

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the PARP Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for PARP Inhibitors and also provide company profiling

• Pipeline products coverage based on various stages of development ranging from late stage till pre-clinical stage

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reasons to Buy

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

• Establish a comprehensive understanding of the current pipeline scenario PARP Inhibitors to formulate effective R&D strategies

• Assess challenges and opportunities that influence PARP Inhibitors R&D

• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

• Devise corrective measures for pipeline projects by understanding PARP Inhibitors pipeline depth and focus of target therapeutics

• Developing strategic initiatives to support your drug development activities

• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for PARP Inhibitors to enhance and expand business potential and scope 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs

• Gaining a full picture of the Competitive Landscape for Evidence based Decisions

 

  • Report Highlights
  • Executive Summary
  • Collaboration, Acquisitions and Licensing
  • Overview
  • Poly (ADP-Ribose) Polymerase
  • Structure and Function of PARP1
  • PARP Homologs
  • Functions of PARP
  • Role in DNA Repair
  • Function in Chromatin Remodeling
  • Effects on Transcription Factors and Epigenetic Factors
  • PARP Inhibitor
  • Market Overview
  • Comparative Analysis of Pipeline & Marketed Products
  • Marketed Drug Candidate Profiles
  • Zejula: Tesaro
  • Product Description
  • Research and Development
  • Zejula Heat Map
  • Product Development Activities
  • Zejula Heat Map
  • Forecasted Sales for Zejula
  • Zejula Analyst Insights
  • Lynparza: AstraZeneca
  • Product Description
  • Research and Development
  • Product Development Activities
  • Lynparza Heat Map
  • Historical and Forecasted Sales for Lynparza
  • Lynparza Analyst Insights
  • Rubraca: Clovis Oncology
  • Product Description
  • Research and Development
  • Product development activities
  • Rubraca Heat Map
  • Forecasted Sales for Rubraca
  • Rubarca Analyst Insights
  • Market Positioning of PARP Inhibitors
  • PARP Inhibitors Market Evolution
  • PARP Inhibitors Class Share Evolution
  • Pipeline Therapeutics
  • Comparative Analysis
  • Late Stage Products (Phase III)
  • Comparative Analysis
  • Veliparib: AbbVie
  • Product Description
  • Research and Development
  • Product Development Activities
  • Forecasted Sales for Veliparib
  • Veliparib Analyst Insights
  • Other Drug Profiles in detailed report
  • Mid Stage Products (Phase II)
  • Comparative Analysis
  • 2X-121: 2X Oncology
  • Product Description
  • Research and Development
  • Product Development Activities
  • Other Drug Profiles in detailed report
  • Early Stage Products (Phase I and IND)
  • Comparative Analysis
  • BGB-290: BeiGene
  • Product Description
  • Research and Development
  • Product Development Activities
  • Other Drug Profiles in detailed report
  • Pre-clinical Stage Products
  • Comparative Analysis
  • NT-125: NewGen Therapeutics
  • Product Description
  • Research and Development
  • Other Drug Profiles in detailed report
  • Therapeutic Assessment: Active Products
  • Assessment by Monotherapy Products
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Dormant Products
  • Comparative Analysis
  • ANG-3186: Angion Biomedica
  • Product Description
  • Product Development Activities
  • Other Drug Profiles in detailed report
  • Discontinued Products
  • Comparative Analysis
  • Iniparib: Sanofi
  • Product Description
  • Research and Development
  • Product Development Activities
  • Other Drug Profiles in detailed report
  • Appendix
  • Report Highlights
  • Executive Summary
  • Collaboration, Acquisitions and Licensing
  • Overview
  • Poly (ADP-Ribose) Polymerase
  • Structure and Function of PARP1
  • PARP Homologs
  • Functions of PARP
  • Role in DNA Repair
  • Function in Chromatin Remodeling
  • Effects on Transcription Factors and Epigenetic Factors
  • PARP Inhibitor
  • Market Overview
  • Comparative Analysis of Pipeline & Marketed Products
  • Marketed Drug Candidate Profiles
  • Zejula: Tesaro
  • Product Description
  • Research and Development
  • Zejula Heat Map
  • Product Development Activities
  • Zejula Heat Map
  • Forecasted Sales for Zejula
  • Zejula Analyst Insights
  • Lynparza: AstraZeneca
  • Product Description
  • Research and Development
  • Product Development Activities
  • Lynparza Heat Map
  • Historical and Forecasted Sales for Lynparza
  • Lynparza Analyst Insights
  • Rubraca: Clovis Oncology
  • Product Description
  • Research and Development
  • Product development activities
  • Rubraca Heat Map
  • Forecasted Sales for Rubraca
  • Rubarca Analyst Insights
  • Market Positioning of PARP Inhibitors
  • PARP Inhibitors Market Evolution
  • PARP Inhibitors Class Share Evolution
  • Pipeline Therapeutics
  • Comparative Analysis
  • Late Stage Products (Phase III)
  • Comparative Analysis
  • Veliparib: AbbVie
  • Product Description
  • Research and Development
  • Product Development Activities
  • Forecasted Sales for Veliparib
  • Veliparib Analyst Insights
  • Other Drug Profiles in detailed report
  • Mid Stage Products (Phase II)
  • Comparative Analysis
  • 2X-121: 2X Oncology
  • Product Description
  • Research and Development
  • Product Development Activities
  • Other Drug Profiles in detailed report
  • Early Stage Products (Phase I and IND)
  • Comparative Analysis
  • BGB-290: BeiGene
  • Product Description
  • Research and Development
  • Product Development Activities
  • Other Drug Profiles in detailed report
  • Pre-clinical Stage Products
  • Comparative Analysis
  • NT-125: NewGen Therapeutics
  • Product Description
  • Research and Development
  • Other Drug Profiles in detailed report
  • Therapeutic Assessment: Active Products
  • Assessment by Monotherapy Products
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Dormant Products
  • Comparative Analysis
  • ANG-3186: Angion Biomedica
  • Product Description
  • Product Development Activities
  • Other Drug Profiles in detailed report
  • Discontinued Products
  • Comparative Analysis
  • Iniparib: Sanofi
  • Product Description
  • Research and Development
  • Product Development Activities
  • Other Drug Profiles in detailed report
  • Appendix

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Table 1: Marketed and Pipeline products for PARP Inhibitors

Table 2: Forecasted Sales for Zejula (2017-2023)

Table 3: Historical and  Forecasted Sales for Lynparza (2014-2023)

Table 4: Forecasted Sales for Rubraca (2017-2023)

Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment

Table 6: Total Drugs for PARP Inhibitors

Table 7: Late Stage Products (Phase III)

Table 8: Forecasted Sales for Veliparib (2018-2023)

Table 9: Forecasted Sales for Talazoparib (2018-2023)

Table 10: Mid  Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical Stage Products

Figure 1: Structural and functional characteristics of PARP1

Figure 2: PARP Family of Proteins

Figure 3: Role of PARP1 in Base Excision Repair (BER)

Figure 4: Role of PARP1 in Transcription Regulation

Figure 5: PARP Inhibition

Figure 6: Marketed and Pipeline products for PARP Inhibitors

Figure 7: Forecasted Sales for Zejula (2017-2023)

Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)

Figure 9: Forecasted Sales for Rubraca (2017-2023)

Figure 10: Market Evolution of PARP Inhibitors (2014-2023)

Figure 11: Total Drugs for PARP Inhibitors

Figure 12: Late Stage Products (Phase III)

Figure 13: Forecasted Sales for Veliparib (2018-2023)

Figure 14: Forecasted Sales for Talazoparib (2018-2023)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Pre-clinical Stage

Figure 18: Assessment by Monotherapy

Figure 19: Assessment by Route of Administration

Figure 20: Assessment by Stage and Route of Administration

Figure 21: Dormant Products

Figure 22: Discontinued Products

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.